-+ 0.00%
-+ 0.00%
-+ 0.00%

Brightlands Venture Partners portfolio firm Vivalyx Omnisol wins EMA breakthrough device status

PUBT·08/27/2026 07:35:09
Listen to the news
Brightlands Venture Partners portfolio firm Vivalyx Omnisol wins EMA breakthrough device status
  • Brightlands Venture Partners portfolio company Vivalyx won EMA Breakthrough Medical Devices status for its Omnisol organ preservation solution.
  • EMA launched the program in April 2026, offering priority scientific advice and enhanced regulatory support toward conformity assessment and commercialization.
  • Vivalyx also secured up to EUR 8.5 million from the EIC Accelerator to advance its organ revitalization technology.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brightlands Venture Partners BV published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.